Prescription Required
Formulation: Patch
Prescription Required
Formulation: Patch
(Generic Alternative)
Select the prescribed dosage
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Minivelle is a prescription hormone replacement therapy (HRT) used to relieve moderate to severe menopausal symptoms and help prevent osteoporosis in postmenopausal women.
It contains estradiol, a form of estrogen that helps replace the hormone the body produces in smaller amounts during and after menopause.
Minivelle belongs to a class of medications called estrogen replacement therapies. These medications help manage symptoms caused by declining estrogen levels and support bone health after menopause.
Minivelle is available as a transdermal patch, which delivers estrogen through the skin and into the bloodstream.
Unlike estrogen tablets taken by mouth, Minivelle releases the hormone gradually through the skin, helping maintain estrogen levels between patch changes.
Minivelle is indicated for treating moderate to severe vasomotor symptoms of menopause, including hot flashes and night sweats. It is also approved for preventing postmenopausal osteoporosis.
By replacing some of the estrogen lost during menopause, Minivelle helps reduce certain symptoms and slow the loss of bone density.
Minivelle is used to treat moderate to severe vasomotor symptoms associated with menopause.
Menopause is a natural stage of life that occurs when menstrual periods permanently stop because the ovaries produce less estrogen and progesterone.
It is usually confirmed after 12 consecutive months without a menstrual period when there is no other medical explanation.
Estrogen plays an important role in regulating body temperature, maintaining bone strength, and supporting the health of several body tissues.
As estrogen levels decline, changes in the body’s temperature regulation can cause symptoms such as hot flashes and night sweats.
Some women also experience sleep disturbances, vaginal dryness, and discomfort during sexual activity.
These symptoms can vary in frequency and severity.
Some women experience mild discomfort, while others have frequent symptoms that interfere with sleep and daily activities.
Minivelle helps replace estrogen and reduce certain effects of declining hormone levels.
Minivelle is primarily prescribed to treat moderate to severe hot flashes and night sweats rather than every symptom associated with menopause.
Minivelle is indicated for the treatment of moderate to severe hot flashes associated with menopause.
Hot flashes are sudden sensations of intense warmth that commonly affect the face, neck, and chest.
They may also spread throughout the body.
During a hot flash, the skin may become red or flushed, and sweating may occur.
Some women also experience a rapid heartbeat, dizziness, or a feeling of discomfort.
Hot flashes develop partly because declining estrogen levels affect the body’s temperature-regulating system.
This system is controlled by an area of the brain called the hypothalamus.
The hypothalamus helps maintain a stable body temperature by controlling sweating, blood vessel activity, and other responses to changes in heat.
During menopause, hormonal changes can make the body’s temperature-control system more sensitive.
As a result, even small temperature changes may trigger sudden feelings of warmth and sweating.
Minivelle provides estrogen replacement, which helps stabilize the processes involved in temperature regulation.
With regular treatment, hot flashes may become less frequent and less severe.
Some women may notice improvements within the first few weeks, although the response varies.
Minivelle helps reduce moderate to severe hot flashes by replacing estrogen and supporting the body’s normal temperature-regulating processes.
Minivelle is also used to relieve night sweats associated with menopause.
Night sweats are episodes of excessive sweating that occur during sleep.
They are similar to hot flashes but develop at night.
Some women wake up feeling unusually warm, sweaty, or uncomfortable.
In severe cases, night sweats may soak clothing or bedding.
These episodes can interrupt sleep and make it difficult to return to sleep.
Repeated sleep disturbances may contribute to tiredness, reduced concentration, and daytime fatigue.
Night sweats occur partly because changes in estrogen levels affect the body’s ability to regulate temperature.
Minivelle helps restore estrogen levels, which may reduce the frequency and severity of nighttime temperature changes.
As night sweats improve, some women may experience fewer nighttime awakenings and better sleep quality.
However, Minivelle is not a sleeping medication.
Its benefits for sleep mainly come from reducing menopause-related symptoms that interrupt rest.
By reducing night sweats, Minivelle may help improve sleep comfort and reduce nighttime disruptions caused by menopause.
Minivelle is also indicated for the prevention of postmenopausal osteoporosis.
Osteoporosis is a condition that causes bones to become weaker and more likely to break.
Bones are living tissues that continuously undergo a process called bone remodeling.
During bone remodeling, the body removes older bone tissue and replaces it with new bone.
Two main types of cells are involved in this process.
Osteoclasts break down old bone tissue, while osteoblasts help build new bone.
Estrogen helps regulate the balance between bone breakdown and bone formation.
After menopause, estrogen levels decline significantly.
This allows bone breakdown to occur more quickly, sometimes faster than the body can replace lost bone tissue.
Over time, bones may become thinner, weaker, and more fragile.
Osteoporosis can increase the risk of fractures, particularly in the hip, spine, and wrist.
Minivelle helps prevent bone loss by replacing estrogen and reducing the rate at which bone tissue is broken down.
This helps maintain bone mineral density and may reduce the loss of bone strength associated with menopause.
However, when Minivelle is used only to prevent osteoporosis, other approved treatments should be carefully considered.
Minivelle is approved for preventing postmenopausal osteoporosis, not as a primary treatment for established osteoporosis.
Your healthcare provider will consider your fracture risk, medical history, and other available treatments before recommending hormone therapy for bone protection.
Minivelle contains estradiol, a form of estrogen that is similar to the hormone naturally produced by the ovaries.
Estrogen is an important hormone that helps regulate several functions in the body.
It supports reproductive tissues, helps regulate body temperature, and plays a role in maintaining bone strength.
During menopause, the ovaries produce much less estrogen.
This decline can affect the brain’s temperature-regulating system and increase the rate of bone loss.
Minivelle helps replace some of the missing estrogen through a transdermal patch applied to the skin.
The hormone passes through the skin and enters the bloodstream, where it acts on estrogen receptors in different tissues.
Replaces Declining Estrogen Levels
Minivelle provides estradiol to help compensate for reduced estrogen production during menopause.
Estradiol binds to estrogen receptors found in many areas of the body, including the brain, bones, and reproductive tissues.
These receptors allow estrogen to influence normal cellular activity.
By restoring some estrogen activity, Minivelle helps reduce symptoms caused by hormonal changes.
The patch releases estrogen gradually, providing a continuous supply between applications.
Helps Regulate Body Temperature
Estrogen helps influence the hypothalamus, the part of the brain responsible for regulating body temperature.
During menopause, declining estrogen levels can make the temperature-control system more sensitive.
This may cause the body to respond to small temperature changes as though it is overheating.
The result can be sudden flushing, sweating, and intense feelings of warmth.
Minivelle helps reduce this sensitivity by restoring estrogen activity.
As a result, hot flashes and night sweats may become less frequent or less severe.
Helps Reduce Bone Breakdown
Estrogen plays an important role in maintaining bone density.
It helps regulate cells that remove old bone tissue and cells that build new bone.
After menopause, lower estrogen levels can cause bone breakdown to occur faster than bone formation.
Over time, this can weaken bones and increase fracture risk.
Minivelle helps slow excessive bone breakdown by restoring estrogen activity in bone tissue.
This can help preserve bone mineral density in postmenopausal women.
However, Minivelle does not replace the need for adequate calcium, vitamin D, appropriate physical activity, and other measures that support bone health.
Delivers Estrogen Through the Skin
Minivelle uses a transdermal delivery system.
This means the hormone enters the bloodstream through the skin instead of passing through the digestive system first.
Unlike oral estrogen, transdermal estrogen avoids the initial processing of the medication by the liver.
This difference can influence how estrogen affects certain liver-produced proteins.
However, transdermal estrogen still enters the bloodstream and can cause systemic side effects.
Minivelle helps reduce menopausal hot flashes and night sweats while supporting bone density by replacing some of the estrogen lost after menopause.
Minivelle begins releasing estradiol after the patch is applied to the skin.
However, the time needed to experience noticeable improvements varies from person to person.
Some women may notice fewer hot flashes or less severe night sweats within the first few weeks of treatment.
More noticeable improvements may develop over several weeks as hormone levels stabilize.
Your response depends on the severity of your symptoms, the prescribed dose, and individual factors.
For osteoporosis prevention, the benefits develop over a longer period.
Bone density changes happen gradually and cannot usually be felt.
Your healthcare provider may recommend bone mineral density testing when appropriate to evaluate your bone health.
Minivelle patches are generally changed twice weekly, following a consistent schedule.
Continue using Minivelle as prescribed and contact your healthcare provider if your symptoms remain troublesome or you develop unwanted effects.
Minivelle is a prescription estrogen patch intended for use on the skin.
It is generally applied twice weekly to clean, dry skin on the lower abdomen or buttocks.
Do not apply the patch to your breasts.
Your healthcare provider will determine the appropriate dose based on whether Minivelle is being used to treat menopausal symptoms or prevent osteoporosis.
Women who still have a uterus may also need a progestogen to reduce the risk of endometrial cancer associated with estrogen treatment.
Minivelle is not appropriate for everyone.
It should not be used during pregnancy or by patients with certain conditions, including unexplained vaginal bleeding, breast cancer, active or previous blood clots, or certain liver diseases.
Estrogen therapy may increase the risk of serious complications, including blood clots and stroke. Risks vary according to individual health factors and treatment circumstances.
Possible side effects include headache, breast tenderness, nausea, and skin irritation.
Use Minivelle at the lowest effective dose for a duration appropriate to your treatment goals and individual risks, with regular reassessment by your healthcare provider.
When Minivelle is prescribed only to prevent osteoporosis, your healthcare provider should first consider non-estrogen medications and assess whether your fracture risk justifies estrogen treatment.Â
Minivelle is a prescription hormone replacement therapy (HRT) patch used to relieve moderate to severe menopausal symptoms and help prevent osteoporosis in postmenopausal women.
It contains estradiol, a form of estrogen that helps replace the hormone the body produces in smaller amounts during and after menopause.
Minivelle is available in different strengths and is applied directly to the skin. The patch gradually releases estrogen through the skin and into the bloodstream.
Before applying Minivelle, choose a clean, dry area of skin on your lower abdomen or buttocks, according to your product instructions.
Do not apply the patch to your breasts, waistline, or areas of skin that are oily, irritated, damaged, or likely to experience frequent rubbing from clothing.
Remove the protective backing and press the patch firmly against your skin for approximately 10 seconds. Make sure the edges are securely attached.
Minivelle patches are usually replaced twice weekly, approximately every three to four days.
When changing your patch, choose a different application site. Wait at least one week before applying another patch to the same area.
If your patch falls off, try reapplying it to another suitable area of clean, dry skin. If it no longer sticks properly, apply a new patch and continue with your original replacement schedule.
Do not wear two patches at the same time unless your healthcare provider specifically instructs you to do so.
Use Minivelle exactly as prescribed and follow your regular patch replacement schedule to maintain consistent estrogen delivery.
Proper application helps ensure that the patch stays attached and delivers estrogen consistently throughout the treatment period.
Follow these steps when applying Minivelle:
Avoid placing Minivelle on areas where tight clothing or waistbands may rub against the patch.
Do not cut or trim Minivelle patches unless your healthcare provider or pharmacist confirms that it is appropriate for your specific product.
Minivelle patches are usually replaced twice weekly.
This means you should change your patch approximately every three to four days.
For example, you may apply a new patch every Monday and Thursday.
Choose two consistent days that fit your weekly routine.
Regular patch replacement helps maintain estrogen delivery and supports symptom control.
Do not leave the same patch on longer than recommended.
Similarly, do not replace patches more frequently than prescribed.
Follow your prescribed replacement schedule, even if your menopausal symptoms have improved.
Minivelle should be applied to an approved area of clean, dry skin on the lower abdomen or buttocks.
Choose an area that is relatively flat and unlikely to experience frequent rubbing.
Avoid applying the patch to your breasts.
Do not place it on your waistline because movement and tight clothing may cause it to loosen.
Avoid applying the patch to skin that is irritated, broken, sunburned, or damaged.
Do not use lotion, oil, powder, or cream on the application site before attaching the patch because these products may prevent it from sticking properly.
When replacing your patch, select a different application site.
Wait at least one week before applying another patch to the same area.
Rotating application sites helps reduce skin irritation and allows previously treated skin to recover.
If your Minivelle patch becomes loose or falls off, try reapplying it to another suitable area of clean, dry skin.
If the patch no longer sticks properly, replace it with a new patch.
Continue following your original patch replacement schedule.
For example, if your patch falls off on Tuesday but your next scheduled replacement is Thursday, apply a replacement patch and change it again on Thursday.
Do not wear two patches at the same time to replace a lost dose.
Avoid using tape or other adhesives to hold the patch in place unless your healthcare provider recommends it.
If your patch repeatedly falls off, contact your healthcare provider or pharmacist for advice about proper application.
If you forget to change your Minivelle patch, apply a new patch as soon as you remember.
Continue with your regular replacement schedule afterward.
Do not apply two patches at once to make up for a missed replacement.
Using additional patches may expose your body to more estrogen than prescribed and increase the risk of side effects.
To help prevent missed doses, consider marking your patch change days on a calendar or setting reminders on your phone.
Do not double your Minivelle dose to make up for a missed patch change.
Used Minivelle patches may still contain some medication after removal.
For this reason, they should be discarded carefully to prevent accidental exposure.
After removing a used patch, fold it in half with the sticky sides pressed together.
This helps prevent the remaining medication from coming into contact with another person.
Place the folded patch in a secure disposal container or follow the disposal instructions provided with your medication.
Keep used patches away from children and pets.
Do not flush Minivelle patches down the toilet.
Always dispose of used Minivelle patches safely because they may still contain estrogen.
Minivelle is intended for use on the skin only.
Do not apply the patch to your breasts, irritated skin, or areas where it may easily become detached.
Tell your healthcare provider if you have a history of blood clots, stroke, certain cancers, liver disease, or unexplained vaginal bleeding.
Minivelle must not be used during pregnancy.
If you still have a uterus, your healthcare provider may prescribe a progestogen alongside Minivelle to reduce the risk of endometrial cancer.
Possible side effects include breast tenderness, headache, nausea, and skin irritation at the application site.
Seek immediate medical attention if you experience chest pain, sudden shortness of breath, severe headache, sudden vision changes, or swelling and pain in one leg.
Continue using Minivelle according to your healthcare provider’s instructions, and attend regular follow-up appointments to review your symptoms, treatment benefits, and potential risks.
Minivelle (Estradiol Transdermal System) is available in the following forms and strength:
Minivelle contains estrogen, which can stimulate the growth of the uterine lining, also called the endometrium.
Women who still have a uterus may have an increased risk of endometrial cancer when using estrogen therapy without a progestogen. This is called unopposed estrogen therapy.
A progestogen helps protect the uterine lining by reducing the excessive growth caused by estrogen.
Your healthcare provider may prescribe a progestogen alongside Minivelle if you still have a uterus.
Tell your healthcare provider if you experience unusual vaginal bleeding, spotting, or bleeding after menopause. These symptoms require medical evaluation because they may indicate changes in the uterine lining.
Estrogen therapy may increase the risk of serious cardiovascular complications, including blood clots and stroke.
Blood clots can develop in deep veins, particularly in the legs. This condition is called deep vein thrombosis (DVT).
A blood clot may also travel to the lungs, causing a pulmonary embolism, which can be life-threatening.
The risk of cardiovascular complications depends on several factors, including age, medical history, smoking, and existing heart or blood vessel conditions.
Evidence about these risks comes partly from studies of oral hormone therapy. Risks with transdermal estrogen may differ, but Minivelle should not be considered completely risk-free.
Seek emergency medical attention if you experience sudden chest pain, difficulty breathing, severe headache, weakness on one side of your body, or swelling and pain in one leg.
Hormone replacement therapy may increase the risk of breast cancer, particularly with certain estrogen-progestogen combinations used for several years.
The risk depends on the type of hormone therapy, how long it is used, and individual health factors.
The breast cancer risk associated with estrogen-only therapy differs from that of combined estrogen-progestogen therapy.
Tell your healthcare provider if you have a personal or family history of breast cancer before starting Minivelle.
Minivelle should not be used by patients with known, suspected, or previous breast cancer unless a specialist determines that an exceptional treatment approach is appropriate.
Report any new breast lumps, nipple discharge, or unusual changes in breast appearance.
Follow your healthcare provider’s recommendations for breast examinations and mammograms during Minivelle treatment.
Minivelle may occasionally affect blood pressure.
Some women using estrogen therapy have experienced clinically significant increases in blood pressure.
However, this reaction is uncommon, and the relationship between estrogen treatment and blood pressure varies among individuals.
Women with existing hypertension should tell their healthcare provider before starting treatment.
Uncontrolled high blood pressure can increase the risk of stroke, heart disease, and other cardiovascular complications.
Your healthcare provider may recommend regular blood pressure measurements while you use Minivelle.
If your blood pressure rises significantly, your treatment may need to be reassessed.
Contact your healthcare provider if your blood pressure readings become consistently higher than usual or you experience concerning symptoms.
Minivelle may worsen certain medical conditions in some patients because estrogen affects several systems in the body.
Tell your healthcare provider if you have asthma, diabetes, epilepsy, migraines, porphyria, systemic lupus erythematosus, or liver hemangiomas.
Porphyria is a group of rare disorders that affect how the body produces heme, a substance needed to form hemoglobin.
Systemic lupus erythematosus is an autoimmune disease that can cause inflammation in different parts of the body.
Liver hemangiomas are usually noncancerous growths made up of blood vessels.
Estrogen therapy may affect symptoms or disease activity in susceptible individuals.
For example, some women may notice changes in migraine frequency, blood sugar levels, or seizure control.
Your healthcare provider may recommend additional monitoring or a different treatment based on your medical history.
Tell your healthcare provider about all existing medical conditions before using Minivelle, even if your symptoms are currently well controlled.
Minivelle should not be used by patients with active liver disease or significant liver dysfunction.
The liver helps process hormones, including estrogen.
When liver function is impaired, the body may have difficulty processing certain medications.
Estrogen therapy has also been associated with cholestatic jaundice, a condition that occurs when the normal flow of bile from the liver is reduced or blocked.
Bile is a digestive fluid that helps the body break down fats.
When bile cannot flow properly, bilirubin may accumulate in the bloodstream.
This can cause yellowing of the skin and eyes, dark urine, pale stools, and itching.
Women who previously developed cholestatic jaundice during pregnancy or estrogen treatment may be more likely to experience it again.
Stop using Minivelle and contact your healthcare provider promptly if you develop yellowing of the skin or eyes, dark urine, or other signs of liver problems.
Some women using estrogen therapy may experience changes in vision or difficulty wearing contact lenses.
Hormonal changes can affect fluid balance and certain tissues in the eyes.
In some cases, these changes may alter how contact lenses fit or feel.
You may notice blurred vision, eye dryness, discomfort, or increased sensitivity while wearing contact lenses.
If you develop persistent contact lens discomfort, consult your healthcare provider or eye care specialist.
However, sudden vision changes may indicate a more serious problem, such as a blood clot affecting the eye.
Seek immediate medical attention if you experience sudden vision loss, severe eye pain, or other significant changes in eyesight.
Estrogen therapy can affect certain proteins involved in transporting thyroid hormones through the bloodstream.
This may change thyroid hormone requirements in women who take thyroid replacement medication.
Your healthcare provider may recommend thyroid function tests after starting or changing Minivelle treatment.
Transdermal estrogen generally has less effect on thyroid-binding proteins than estrogen taken by mouth, but monitoring may still be appropriate.
Estrogen can also affect calcium regulation in certain medical conditions.
Low blood calcium levels, called hypocalcemia, are not a typical effect of combining Minivelle with thyroid medication.
However, women with conditions that affect calcium balance may require additional monitoring.
Tell your healthcare provider if you take thyroid medication or have a disorder affecting calcium levels before starting Minivelle.
Unusual vaginal bleeding during Minivelle treatment should not be ignored.
Estrogen stimulates the uterine lining, which may cause it to become thicker.
Women who still have a uterus may be at greater risk of excessive endometrial growth when estrogen is used without a progestogen.
This condition is called endometrial hyperplasia.
Some forms of endometrial hyperplasia may increase the risk of endometrial cancer.
Bleeding may occur as spotting, heavier-than-expected bleeding, or bleeding after menopause.
Although not every episode of bleeding indicates a serious condition, it is important to identify the cause.
Your healthcare provider may recommend a pelvic examination, ultrasound, or other tests.
Report any unexpected, persistent, or recurring vaginal bleeding to your healthcare provider, especially if you have already reached menopause.
Minivelle may cause allergic reactions in some women, particularly those who are sensitive to estradiol or other ingredients in the patch.
An allergic reaction occurs when the immune system responds to a substance it mistakenly identifies as harmful.
Mild reactions may cause itching, redness, skin irritation, or a rash around the application site.
In rare cases, estrogen therapy may cause a severe allergic reaction called anaphylaxis.
Another serious reaction is angioedema, which causes sudden swelling beneath the skin.
Angioedema may affect the face, lips, tongue, throat, or other parts of the body.
Swelling of the tongue or throat can make breathing or swallowing difficult.
Women with hereditary angioedema may also experience worsening symptoms during estrogen treatment.
Remove the Minivelle patch and seek emergency medical attention if you experience difficulty breathing, swelling of the tongue or throat, or other signs of a severe allergic reaction.
Minivelle should not be used during pregnancy.
The medication contains estradiol, which is intended to replace declining estrogen levels during menopause.
Minivelle is not intended for use during pregnancy and does not provide benefits for maintaining a healthy pregnancy.
If you are pregnant, planning to become pregnant, or think you may be pregnant, tell your healthcare provider before starting treatment.
If pregnancy occurs while using Minivelle, contact your healthcare provider promptly.
Your healthcare provider can determine whether further evaluation is necessary.
Do not use Minivelle during pregnancy. If you become pregnant during treatment, remove the patch and contact your healthcare provider.
Minivelle should not be used by women with known, suspected, or previous breast cancer.
It is also contraindicated in women with known or suspected estrogen-dependent cancers.
Some cancers contain estrogen receptors that allow estrogen to influence their growth.
Because Minivelle provides estrogen replacement, it may stimulate certain hormone-sensitive cancer cells.
Women with a history of endometrial cancer or other hormone-sensitive cancers should discuss their medical history with their healthcare provider.
Your healthcare provider will review your cancer history and determine whether another treatment for menopausal symptoms is more appropriate.
Do not use Minivelle if you have known, suspected, or previous breast cancer or a known estrogen-dependent cancer.
Smoking and certain medical conditions may increase the risk of cardiovascular complications during hormone replacement therapy.
These conditions include high blood pressure, diabetes, obesity, and elevated cholesterol levels.
Smoking can damage blood vessels and increase the risk of blood clots, stroke, and heart disease.
High cholesterol can contribute to the buildup of fatty deposits inside arteries.
This condition is called atherosclerosis.
Atherosclerosis can narrow blood vessels and reduce blood flow to important organs.
Women with several cardiovascular risk factors may require additional evaluation before starting Minivelle.
Your healthcare provider will consider your age, medical history, smoking status, and other risk factors when determining whether estrogen therapy is appropriate.
Tell your healthcare provider if you smoke, have high cholesterol, or have a history of cardiovascular disease before using Minivelle.
Minivelle may affect triglyceride levels in some women.
Triglycerides are a type of fat found in the bloodstream.
The body uses triglycerides to store energy, but excessively high levels can increase the risk of certain health problems.
Women who already have elevated triglycerides may experience further increases during estrogen treatment.
In severe cases, very high triglyceride levels can cause pancreatitis.
Pancreatitis is a serious condition involving inflammation of the pancreas.
Symptoms may include severe upper abdominal pain, nausea, vomiting, and pain that spreads to the back.
Your healthcare provider may recommend blood tests to monitor triglyceride levels if you have a history of this condition.
Stop using Minivelle and seek prompt medical attention if you develop severe abdominal pain or symptoms suggesting pancreatitis.
Minivelle may interact with certain prescription medications, over-the-counter products, and herbal supplements.
Some medications can change how quickly the body breaks down estrogen.
This may affect the amount of estradiol circulating in the bloodstream.
For example, certain medications used to treat seizures or infections may reduce estrogen levels and potentially decrease the effectiveness of Minivelle.
Other medications may increase estrogen exposure and the risk of unwanted side effects.
Herbal products containing St. John’s wort may also affect estrogen metabolism.
Tell your healthcare provider about all medications and supplements you currently use.
Your healthcare provider may need to review your treatment plan when another medication is started or stopped.
Do not start, stop, or change another medication or herbal supplement without consulting your healthcare provider.
Hormone therapy is not recommended for preventing dementia or memory loss.
Dementia is a condition that affects memory, thinking, communication, and the ability to perform everyday activities.
Certain studies have examined whether menopausal hormone therapy affects dementia risk.
The Women’s Health Initiative Memory Study found an increased risk of probable dementia in women aged 65 years and older who began certain oral hormone therapy regimens.
However, these findings do not establish that Minivelle causes dementia at the same rate.
The study involved oral estrogen formulations, and the effects of transdermal estradiol may differ.
Research has not established that Minivelle prevents dementia or cognitive decline.
For this reason, Minivelle should not be prescribed for the purpose of improving memory or preventing Alzheimer’s disease.
Your healthcare provider will consider your age, medical history, and treatment goals when assessing the benefits and risks of hormone replacement therapy.
Do not use Minivelle to prevent dementia or memory loss. Discuss any new or worsening memory problems with your healthcare provider.Â
No. Minivelle should not be used during pregnancy because it contains estradiol, a form of estrogen intended to treat menopausal symptoms. Minivelle is not approved for use during pregnancy and does not provide benefits for maintaining a healthy pregnancy. It is also not recommended during breastfeeding because estrogen may pass into breast milk and reduce milk production. If you become pregnant while using Minivelle, remove the patch and contact your healthcare provider. If you are breastfeeding, ask your healthcare provider about a more suitable treatment.
Do not wear two Minivelle patches at the same time unless your healthcare provider specifically prescribes this dosing arrangement. Using more patches than recommended may increase estrogen exposure and the risk of side effects, including breast tenderness, nausea, headaches, and abnormal vaginal bleeding. Higher estrogen exposure may also increase the risk of serious complications in susceptible patients. If your patch falls off or you forget to replace it, follow the missed-dose instructions rather than applying extra patches. Always use the number and strength of patches prescribed by your healthcare provider.
Yes. Estradiol patches are sometimes prescribed as part of estrogen-based gender-affirming hormone therapy (GAHT). This treatment helps people develop or maintain physical characteristics associated with estrogen. Transdermal estrogen may be preferred for some patients, particularly those with an increased risk of blood clots or cardiovascular problems. It may also provide steadier hormone levels than certain estrogen injections. However, Minivelle is not specifically approved for gender-affirming hormone therapy, so this use is considered off-label. Your healthcare provider will determine the appropriate estradiol formulation, dosage, and monitoring schedule based on your individual needs and medical history.
Minivelle patches should be stored at room temperature, generally between 20°C and 25°C (68°F and 77°F). Keep the patches in their original protective pouches until you are ready to apply them. Avoid exposing the medication to excessive heat or moisture because improper storage may affect the patch’s quality and adhesive properties. Do not open the pouch until immediately before use. Keep unused and used patches out of reach of children and pets. When disposing of a used patch, fold it in half with the sticky sides together and follow the product’s disposal instructions. Do not flush used patches down the toilet.
| Generic name: | Estradiol Transdermal System |
|---|---|
| Formulation: | Patch |
| Strength(s): | 0.05mg, 0.075mg |
| Quantities Available: | 8 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Minivelle (estradiol transdermal system) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Minivelle patches are available in strengths of 0.025 mg, 0.0375 mg, 0.05 mg, 0.075 mg, and 0.1mg of estradiol per day. The patches are typically applied twice a week (one patch every 3 to 4 days). For a 90-day supply, this means you would order 24 patches (12 weeks × 2 patches per week).
Yes, we sell the estradiol transdermal system on our website. You can enjoy low prices when you order through us. To purchase the estradiol transdermal system, you will need a valid prescription from your healthcare provider. We require this prescription to dispense the medication safely and appropriately. You can submit your prescription by mailing it to us, faxing it, or uploading it through your online account.
Yes, we ship Minivelle (estradiol transdermal system) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Minivelle (Estradiol Transdermal System). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Minivelle (Estradiol Transdermal System).
REVIEWS